SVRA

Savara Inc. [SVRA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SVRA Stock Summary

Top 10 Correlated ETFs

SVRA


Top 10 Correlated Stocks

SVRA


In the News

06:40 29 Mar 2024 SVRA

3 stocks to turn $100 into $1,000 in 2024

The previous year was prosperous for many investors, resulting in significant gains in the stock market. The outlook for 2024 seems promising, especially in the technology sector.

08:05 29 Mar 2024 SVRA

Savara to Present at Two Upcoming Healthcare Conferences

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences: Guggenheim 6th Annual Biotechnology Conference February 7, 2024 at 8:30am PT/ 11:30am ET Fireside Chat St. Regis Hotel, New York City, NY Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 at 7:40am PT / 10:40am ET Co.

07:29 29 Mar 2024 SVRA

3 Penny Stocks to Provide 1,000% Returns Over the Next Decade

While penny stocks promise substantial potential gains, the reality is that sub-$5 stocks are among the riskiest investments. Their low price often reflects underlying issues like weak business models, high debt, dwindling market share, and uncertain prospects.

09:12 29 Mar 2024 SVRA

The 3 Best Penny Stocks to Buy Now: September 2023

A new month arrives and with it comes new investment opportunities. We will not always need such a large capital to make our investments, for these penny stocks present us with good opportunities that we can take advantage of, with little capital but perhaps with great returns.

04:05 29 Mar 2024 SVRA

Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm PT. A live webcast of the presentation will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clin.

11:50 29 Mar 2024 SVRA

Savara: A Speculative Play

Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed for a rare affliction that has no approved therapies and has a pivotal readout coming up in the second quarter of 2024. An update investment analysis around Savara follows in the paragraphs below.

08:05 29 Mar 2024 SVRA

Savara to Present at the Jefferies Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT. A live webcast of the fireside chat will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical s.

12:32 29 Mar 2024 SVRA

Why Shares of Savara Jumped on Tuesday

Savara is a clinical-stage pharmaceutical company with no revenue. The company expects a top-line readout on molgramostim in the second quarter of 2024.

04:05 29 Mar 2024 SVRA

Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 1:20pm ET. A live webcast of the presentation will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

03:47 29 Mar 2024 SVRA

Why Shares of Savara Soared This Week

The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.

SVRA Financial details

Company Rating
Neutral
Market Cap
663.11M
Income
-52.38M
Revenue
0
Book val./share
0.78
Cash/share
0.9
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-14.85
Forward P/E
-12.77
PEG
-5.44
P/S
-
P/B
4.8
P/C
5.53
P/FCF
-13.05
Quick Ratio
18.88
Current Ratio
18.98
Debt / Equity
0.19
LT Debt / Equity
0.19
-
-
EPS (TTM)
-0.32
EPS next Y
-0.39
EPS next Q
-0.1
EPS this Y
32%
EPS next Y
21.48%
EPS next 5Y
-251.85%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-10.5%
-
-
-
-
SMA20
-3.76%
SMA50
12.5%
SMA100
37.29%
Inst Own
42.71%
Inst Trans
0.73%
ROA
-26%
ROE
-43%
ROC
-0.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
138.15M
Shs Float
66.74M
-
-
-
-
Target Price
-
52W Range
1.63-5.7
52W High
-0.4%
52W Low
+398%
RSI
51.8
Rel Volume
1.09
Avg Volume
828.4K
Volume
904.12K
Perf Week
2.47%
Perf Month
-0.4%
Perf Quarter
32.1%
Perf Half Y
34.59%
-
-
-
-
Beta
0.77
-
-
Volatility
0.06%, 0.24%
Prev Close
2.68%
Price
4.98
Change
0.4%

SVRA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-2.62-0.86-0.34-0.25-0.33
Operating cash flow per share
-1.13-0.67-0.3-0.23-0.31
Free cash flow per share
-1.13-0.73-0.3-0.23-0.31
Cash per share
3.041.391.20.820.98
Book value per share
2.541.091.080.710.85
Tangible book value per share
2.260.880.990.640.78
Share holders equity per share
2.541.091.080.710.85
Interest debt per share
0.640.450.210.170.16
Market cap
179.32M68.21M166.06M236.8M776.46M
Enterprise value
155.07M70.61M157.84M210.84M776.61M
P/E ratio
-1.71-1.33-3.67-6.08-14.2
Price to sales ratio
0265.39000
POCF ratio
-3.97-1.71-4.14-6.85-15.21
PFCF ratio
-3.96-1.58-4.14-6.85-15.12
P/B Ratio
1.761.061.152.25.53
PTB ratio
1.761.061.152.25.53
EV to sales
0274.74000
Enterprise value over EBITDA
-6.2-1.48-3.92-5.57-12.98
EV to operating cash flow
-3.44-1.77-3.94-6.1-15.21
EV to free cash flow
-3.43-1.64-3.93-6.1-15.12
Earnings yield
-0.59-0.75-0.27-0.16-0.07
Free cash flow yield
-0.25-0.63-0.24-0.15-0.07
Debt to equity
0.250.390.180.240.19
Debt to assets
0.190.260.150.190.15
Net debt to EBITDA
0.97-0.050.20.690
Current ratio
11.410.4111.2621.9815.66
Interest coverage
1.13K-33.27-18.18-441.350
Income quality
0.580.80.930.910.93
Dividend Yield
00.03000
Payout ratio
0-0.04000
Sales general and administrative to revenue
055.5000
Research and developement to revenue
0136.33000
Intangibles to total assets
0.080.120.060.080.06
Capex to operating cash flow
00.08000.01
Capex to revenue
0-12.82000
Capex to depreciation
-0.15-4.75-0.16-0.05-1.69
Stock based compensation to revenue
019.87000
Graham number
12.254.592.872.012.52
ROIC
-0.83-0.57-0.26-0.3-0.36
Return on tangible assets
-0.84-0.6-0.27-0.3-0.33
Graham Net
2.190.830.970.630.76
Working capital
113.19M76.95M150.34M123.09M155.35M
Tangible asset value
90.59M52.17M133.22M97.12M129.41M
Net current asset value
89.56M51.76M132.9M96.96M128.76M
Invested capital
0.250.390.180.240.19
Average receivables
1.65M1.66M1.42M1.05M979.5K
Average payables
3.64M3M2.02M1.39M2.42M
Average inventory
-808.5K-1.66M-1.42M454.5K1.03M
Days sales outstanding
02.41K000
Days payables outstanding
1.23K27.03K1.44K2.92K7.31K
Days of inventory on hand
-584.36-17.66K-1.14K4.49K0
Receivables turnover
00.15000
Payables turnover
0.30.010.250.130.05
Inventory turnover
-0.62-0.02-0.320.08175K
ROE
-1.03-0.79-0.31-0.36-0.39
Capex per share
0-0.06000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.07-0.05-0.07-0.1-0.09
Operating cash flow per share
-0.06-0.08-0.07-0.08-0.09
Free cash flow per share
-0.06-0.08-0.07-0.08-0.09
Cash per share
0.820.750.691.020.9
Book value per share
0.710.640.570.890.78
Tangible book value per share
0.640.570.50.830.72
Share holders equity per share
0.710.640.570.890.78
Interest debt per share
0.170.180.180.170.15
Market cap
236.8M297.92M488.95M621.22M845.26M
Enterprise value
210.84M290.15M492.48M619.95M845.42M
P/E ratio
-5.34-9.04-10.68-9.36-13.13
Price to sales ratio
00000
POCF ratio
-27.37-24.77-47.6-47.2-54.17
PFCF ratio
-27.36-24.77-46.58-47.05-54.09
P/B Ratio
2.23.035.574.246.02
PTB ratio
2.23.035.574.246.02
EV to sales
00000
Enterprise value over EBITDA
-19.5-22.53-40.39-34.41-48.13
EV to operating cash flow
-24.37-24.13-47.94-47.11-54.18
EV to free cash flow
-24.36-24.12-46.92-46.95-54.1
Earnings yield
-0.05-0.03-0.02-0.03-0.02
Free cash flow yield
-0.04-0.04-0.02-0.02-0.02
Debt to equity
0.240.270.30.180.19
Debt to assets
0.190.20.220.150.15
Net debt to EBITDA
2.40.6-0.290.07-0.01
Current ratio
21.9823.918.3318.9815.66
Interest coverage
169.92-15.83-17.24-12.50
Income quality
0.841.140.90.790.97
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.080.080.090.060.06
Capex to operating cash flow
000.0200
Capex to revenue
00000
Capex to depreciation
-0.12-0.17-9.38-0.69-0.36
Stock based compensation to revenue
00000
Graham number
1.070.880.981.421.25
ROIC
-0.09-0.08-0.1-0.1-0.11
Return on tangible assets
-0.09-0.07-0.1-0.1-0.1
Graham Net
0.630.560.490.810.7
Working capital
123.09M112.7M102.02M161.13M155.35M
Tangible asset value
97.12M87.44M76.93M136.05M129.41M
Net current asset value
96.96M86.52M75.78M134.57M128.76M
Invested capital
0.240.270.30.180.19
Average receivables
907.5K997K1.02M976K978K
Average payables
1.11M1.45M2.04M2.86M3.36M
Average inventory
1.03M1.81M1.57M1.15M366K
Days sales outstanding
00000
Days payables outstanding
2.86K6.16K9.38K4.6K4.78K
Days of inventory on hand
4.4K6.15K5.85K1.05K0
Receivables turnover
00000
Payables turnover
0.030.010.010.020.02
Inventory turnover
0.020.010.020.0966K
ROE
-0.1-0.08-0.13-0.11-0.11
Capex per share
00000

SVRA Frequently Asked Questions

What is Savara Inc. stock symbol ?

Savara Inc. is a US stock , located in Austin of Tx and trading under the symbol SVRA

What is Savara Inc. stock quote today ?

Savara Inc. stock price is $4.98 today.

Is Savara Inc. stock public?

Yes, Savara Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap